The EU Vaccine Industry in Figures

Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.

Find out more

Vaccines: a tool for spending smart

Effective vaccination programmes ease pressure on budgets and allow resources to focus on other healthcare areas and medical innovation

Find out how

-->

Prevention First

Vaccination at the Heart of Public Health. Vaccines Europe calls on EU policy-makers to develop a comprehensive vaccination strategy through five core policy asks.

Read more

Vaccine Market Access in the EU

How long for a vaccine to reach European Population? 6,4 years is the median time lag between marketing authorisation and effective population access

Find out more

An industry for healthy lives

As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe as well as small and medium sized enterprises.
Find out more about our services, the opportunites we offer and how to become a member.

Find out how to become a member

Latest News

RSS

Vaccines Europe welcomes the appointment of new ECDC Director

2017 03 24 Written by Vaccines Europe

Vaccines Europe welcomes the appointment of Dr. Andrea Ammon as Director of the European Centre for Disease Prevention and Control (ECDC) for the next five years (2017-2022). Vaccines Europe supports a strong leadership role of the ECDC, together with a clear ECDC strategy and vision towards vaccine preventable diseases in Europe.

Global partnership launched to prevent epidemics with new vaccines

2017 01 20 Written by Vaccines Europe

A global coalition to create new vaccines for emerging infectious diseases, was launched on 18th January at the World Economic Forum in Davos, Switzerland. This coalition is funded by the governments of Germany, Japan and Norway, plus the Bill & Melinda Gates Foundation and the Wellcome Trust and supported by several leading vaccine companies.

Please find the official announcement here, and the IFPMA support statement here.

Vaccines Europe paper on antimicrobial resistance

2016 11 16 Written by Vaccines Europe

The frequency of antimicrobial resistance (AMR) is increasing in Europe and constitutes a serious danger to public health. Evidence has shown that existing vaccines have a positive impact in reducing AMR. In addition, new vaccines could play a critical role in preventing multi-drug resistant infections, such as from S. aureus, C. difficile and E. coli.

Access and download our paper here.

See all News